This paper was published through Galoá and has a deposited DOI. To cite this paper, use one of the standards below:
In case you are one of the co-authors and want to register this paper in your Lattes, use the following code: doi > 10.17648/bctrims-2023-167466
If you've NEVER registered a DOI in your Lattes, check our tutorial!Introduction: Multiple sclerosis (MS) is a disease that leads to a central nervous system (CNS) inflammatory lesions and demyelination. The current accepted hypothesis for the etiology of MS corresponds to an autoimmune process triggered by environmental and genetic factors. Also, it is noted that viruses play an important role in MS pathogenesis as the human endogenous retroviruses (HERVs) and Epstein-Barr virus (EBV). Those are believed to be intrinsically involved with the disease’s pathogenesis, stage and progression. Objectives: This abstract’s objective is to bring attention to the issue of MS correlation to EBV and HERV proteins. Methods: This work is a non-systematic review. All articles used were searched in the public databases PubMed, Medline, ScienceDirect, SciELO and Cochrane. The process of localizing these articles was done by searching for terms related to multiple sclerosis, HERV, EBV and selecting the most relevant articles available in English. Results: It has been shown that EBV possesses the ability to promote epigenetics alterations. In MS context, it was demonstrated that EBV infection induced HERV-W elements (syncytin-1 and MSRV) activation in astrocytes and blood cells through NF-kB pathway. Also it was demonstrated that MS patients possess higher levels of syncytin-1. Furthermore, HERV proteins may trigger both innate and adaptive immune responses. Conclusion: In conclusion, EBV’s epigenetic ability inducing HERV’s activation in a variety of cells may play a role in MS pathogenesis. This is a crucial piece in the disease’s puzzle, once there are new treatments for MS under development focusing specifically on HERV mechanism, such as monoclonal antibodies targeting MSRV-Env protein and antiretroviral therapy.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper